Atlas Trials

Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma Patients

Clinical trial NCT01994850 · COMPLETED

Trial details

NCT number
NCT01994850
Sponsor
Abramson Cancer Center at Penn Medicine
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
CD30 Positive Primary Mediastinal Large B-cell LymphomaCD30-Positive Diffuse Large B-Cell LymphomaCD30-Positive Gray Zone Lymphoma
Start date
2013-11-01
Primary completion
2017-08-01
Enrollment
32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.